Promising Therapeutic Potential of Blarcamesine Sparks Buy Rating for Anavex Life SciencesValuation and Risks. We utilize a discounted cash flow (DCF)-driven methodology, which ascribes a total value of ~$1.8B to blarcamesine alone without ascribing value to any other pipeline assets. We employ a 20% probability of approval in Parkinson's disease dementia (PDD); and 40% in AD. Further, we apply a 12% discount rate and 1% terminal growth rate. We derive a total firm value of $1.8B, which yields a 12-month price objective of $20 per share, assuming ~89.5M shares outstanding as of end-F2026.